Guangdong HEC Technology

Guangdong HEC Technology Holding Co., Ltd. (“Guangdong HEC Technology”) is a major Chinese conglomerate with leading positions in pharmaceuticals, new chemical materials, electronic components, and energy materials. Its pharmaceutical division has over 150 approved drugs worldwide, including China’s top-selling oseltamivir brand “Kewei,” multiple Class I innovative drugs under development or review by the NMPA, and an extensive pipeline featuring small molecules and biologics/biosimilars. As of mid-2025 it had one innovative drug under market review by the NMPA, ten more in Phase II/III trials, over 100 R&D projects including 49 Class I new drugs, robust sales coverage across China’s hospital system, global reach into Europe/North America/etc., repeated recognition among China’s most innovative pharma companies since at least 2017–2024.